Long-Term Risk of Arterial Thrombosis After Intracerebral Hemorrhage: MUCH-Italy

Background: The identification of patients surviving an acute intracerebral hemorrhage who are at a long-term risk of arterial thrombosis is a poorly defined, crucial issue for clinicians.

Methods: In the setting of the MUCH-Italy (Multicenter Study on Cerebral Haemorrhage in Italy) prospective observational cohort, we enrolled and followed up consecutive 30-day intracerebral hemorrhage survivors to assess the long-term incidence of arterial thrombotic events, to assess the impact of clinical and radiological variables on the risk of these events, and to develop a tool for estimating such a risk at the individual level. Primary end point was a composite of ischemic stroke, myocardial infarction, or other arterial thrombotic events. A point-scoring system was generated by the β-coefficients of the variables independently associated with the long-term risk of arterial thrombosis, and the predictive MUCH score was calculated as the sum of the weighted scores.

Results: Overall, 1729 patients (median follow-up time, 43 months [25th to 75th percentile, 69.0]) qualified for inclusion. Arterial thrombotic events occurred in 169 (9.7%) patients. Male sex, diabetes, hypercholesterolemia, atrial fibrillation, and personal history of coronary artery disease were associated with increased long-term risk of arterial thrombosis, whereas the use of statins and antithrombotic medications after the acute intracerebral hemorrhage was associated with a reduced risk. The area under the receiver operating characteristic curve of the MUCH score predictive validity was 0.716 (95% CI, 0.56-0.81) for the 0- to 1-year score, 0.672 (95% CI, 0.58-0.73) for the 0- to 5-year score, and 0.744 (95% CI, 0.65-0.81) for the 0- to 10-year score. C statistic for the prediction of events that occur from 0 to 10 years was 0.69 (95% CI, 0.64-0.74).

Conclusions: Intracerebral hemorrhage survivors are at high long-term risk of arterial thrombosis. The MUCH score may serve as a simple tool for risk estimation.

References

. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurol. 2021; 20(10):842-853. DOI: 10.1016/S1474-4422(21)00264-7. View

Li L, Poon M, Samarasekera N, Perry L, Moullaali T, Rodrigues M . Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies. Lancet Neurol. 2021; 20(6):437-447. PMC: 8134058. DOI: 10.1016/S1474-4422(21)00075-2. View

Hemphill 3rd J, Greenberg S, Anderson C, Becker K, Bendok B, Cushman M . Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015; 46(7):2032-60. DOI: 10.1161/STR.0000000000000069. View

Uno H, Cai T, Pencina M, DAgostino R, Wei L . On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med. 2011; 30(10):1105-17. PMC: 3079915. DOI: 10.1002/sim.4154. View

Greenberg S, Ziai W, Cordonnier C, Dowlatshahi D, Francis B, Goldstein J . 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2022; 53(7):e282-e361. DOI: 10.1161/STR.0000000000000407. View

Salman R, Minks D, Mitra D, Rodrigues M, Bhatnagar P, du Plessis J . Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurol. 2019; 18(7):643-652. PMC: 7645733. DOI: 10.1016/S1474-4422(19)30184-X. View

Fluss R, Faraggi D, Reiser B . Estimation of the Youden Index and its associated cutoff point. Biom J. 2005; 47(4):458-72. DOI: 10.1002/bimj.200410135. View

Li L, Murthy S . Cardiovascular Events After Intracerebral Hemorrhage. Stroke. 2022; 53(7):2131-2141. PMC: 9247019. DOI: 10.1161/STROKEAHA.122.036884. View

Salman R, Dennis M, Sandercock P, Sudlow C, Wardlaw J, Whiteley W . Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage: Extended Follow-up of the RESTART Randomized Clinical Trial. JAMA Neurol. 2021; 78(10):1179-1186. PMC: 8417806. DOI: 10.1001/jamaneurol.2021.2956. View

10.

Mehran R, Rao S, Bhatt D, Gibson C, Caixeta A, Eikelboom J . Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011; 123(23):2736-47. DOI: 10.1161/CIRCULATIONAHA.110.009449. View

11.

Tibshirani R . The lasso method for variable selection in the Cox model. Stat Med. 1997; 16(4):385-95. DOI: 10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3. View

12.

Wada R, Aviv R, Fox A, Sahlas D, Gladstone D, Tomlinson G . CT angiography "spot sign" predicts hematoma expansion in acute intracerebral hemorrhage. Stroke. 2007; 38(4):1257-62. DOI: 10.1161/01.STR.0000259633.59404.f3. View

13.

Murthy S, Zhang C, Diaz I, Levitan E, Koton S, Bartz T . Association Between Intracerebral Hemorrhage and Subsequent Arterial Ischemic Events in Participants From 4 Population-Based Cohort Studies. JAMA Neurol. 2021; 78(7):809-816. PMC: 8094038. DOI: 10.1001/jamaneurol.2021.0925. View

14.

Harrell Jr F, Lee K, Mark D . Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15(4):361-87. DOI: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4. View

15.

Pezzini A, Grassi M, Paciaroni M, Zini A, Silvestrelli G, Iacoviello L . Obesity and the risk of intracerebral hemorrhage: the multicenter study on cerebral hemorrhage in Italy. Stroke. 2013; 44(6):1584-9. DOI: 10.1161/STROKEAHA.111.000069. View

16.

Shoamanesh A, Selim M . Use of Lipid-Lowering Drugs After Intracerebral Hemorrhage. Stroke. 2022; 53(7):2161-2170. PMC: 9248990. DOI: 10.1161/STROKEAHA.122.036889. View

17.

Gaist D, Hald S, Rodriguez L, Clausen A, Moller S, Hallas J . Association of Prior Intracerebral Hemorrhage With Major Adverse Cardiovascular Events. JAMA Netw Open. 2022; 5(10):e2234215. PMC: 9530971. DOI: 10.1001/jamanetworkopen.2022.34215. View

18.

. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019; 18(5):439-458. PMC: 6494974. DOI: 10.1016/S1474-4422(19)30034-1. View

19.

Casolla B, Moulin S, Kyheng M, Henon H, Labreuche J, Leys D . Five-Year Risk of Major Ischemic and Hemorrhagic Events After Intracerebral Hemorrhage. Stroke. 2019; 50(5):1100-1107. DOI: 10.1161/STROKEAHA.118.024449. View

20.

Aho K, Harmsen P, Hatano S, MARQUARDSEN J, Smirnov V, Strasser T . Cerebrovascular disease in the community: results of a WHO collaborative study. Bull World Health Organ. 1980; 58(1):113-30. PMC: 2395897. View